Healthcare M&A: When 2 + 2 Can Equal 5

The standard theory of mergers and acquisitions is straightforward: Put two similar businesses together, eliminate overlapping costs, gain purchasing leverage, expand geographic reach and improve margins. Healthcare has produced plenty of transactions built on exactly that premise.

It works. It is also not where all of the interesting deals come from.

Healthcare is unusually interconnected. Providers, payers, technology companies, diagnostics businesses, medical-device manufacturers, pharmaceutical companies and outsourced service providers operate in different parts of the same economic system. A capability developed in one corner of that system can be worth far more when combined with assets somewhere else.

That creates an M&A dynamic that is easy to overlook.

The most logical buyer for a healthcare company isn’t always its largest competitor. Sometimes it isn’t even a competitor.

It may be a company several steps away in the value chain that can combine an acquired capability with assets the seller doesn’t have: distribution, reimbursement infrastructure, clinical access, proprietary data, an installed customer base or a broader technology platform.

In those transactions, the arithmetic isn’t 2 + 2 = 4. The objective is 2 + 2 = 5.

Consider a healthcare technology company with a differentiated product but limited distribution. To another technology company, it may be worth a conventional revenue or EBITDA multiple. To a strategic buyer with thousands of existing provider relationships, the same product could immediately become a new source of revenue across an installed customer base.

Same company. Same product. Very different math.

A diagnostics company may have strong clinical capabilities but limited access to risk-bearing organizations. A Medicare Advantage or value-based care platform may see something different: an opportunity to identify risk earlier, improve medication management, reduce adverse events or capture information that improves both care and economics.

A healthcare services business may possess a workflow, provider network or specialized capability that looks modest on a standalone basis but becomes considerably more valuable inside a larger platform.

The distinction matters because traditional M&A thinking often begins with the question, “Who buys companies like this?”

In healthcare, a better question is often, “Who could create the most value with what this company has built?”

Those sound like variations of the same question. They aren’t.

The first tends to produce a list of direct competitors and financial sponsors. The second requires a broader understanding of the healthcare ecosystem and the ways capabilities, economics and incentives intersect across it.

This is why healthcare sector expertise in M&A should extend beyond knowing which private-equity firms own which platforms.

That knowledge matters. But the more valuable insight is often understanding the commercial logic that connects businesses in adjacent sectors.

A technology may improve physician productivity. A diagnostic may reduce downstream medical costs. A service may shift care from an expensive setting to a lower-cost one. A dataset may become substantially more valuable when embedded in another organization’s workflow. A clinical capability may give a larger platform entry into a new specialty, customer base or reimbursement channel.

The buyer willing to pay the most may be the one that sees an opportunity the seller cannot fully exploit on its own.

That has implications for how healthcare companies should be brought to market.

Broad auctions have an important place in M&A. For large, scaled businesses with an obvious universe of capable buyers, competition among many bidders can be highly effective. If a broad auction process makes sense, we’ll do it, and we’ve done it well.

But unless you’re a large, scaled business, most healthcare companies are better served by a more targeted process.

That isn’t an argument against competition. It is an argument for making sure the right companies are competing.

There is a certain comfort in a buyer list with 150 names on it. It looks comprehensive. It also looks like someone did a lot of work.

But market coverage and strategic insight are not the same thing.

A list of 150 potential buyers can easily miss the five or ten organizations for which an asset has unusual strategic significance.

In healthcare, thoughtful buyer selection can matter more than buyer count.

It can also produce a better strategic discussion. The value proposition to a direct competitor may center on market share and operating efficiencies. To a technology company, it may be data or workflow integration. To a payer, it may be medical-cost reduction. To a provider platform, it may be access to new capabilities or revenue streams.

The underlying business hasn’t changed.

Its value to each buyer has.

That is where healthcare transactions differ from selling a more interchangeable asset. Healthcare companies sit inside complex networks of reimbursement, clinical workflow, regulation, data and patient behavior. Strategic value often depends on how one organization’s assets interact with another’s.

None of this means “synergy” should become a polite M&A term for wishful thinking after closing. Buyers are right to discount opportunities that can’t be quantified or executed.

A combination deserves a premium only when there is a credible path to additional revenue, improved economics or a defensible competitive advantage.

But the strongest healthcare deals often begin with precisely that insight: The business is worth more inside a particular strategic context than it is on a spreadsheet by itself.

That is why some of the most important work in healthcare M&A happens before a buyer is contacted. It is understanding where the company sits in the ecosystem, what it does unusually well, which organizations could amplify those capabilities and where the economic benefit from the combination would accrue.

Consolidation will remain an important part of healthcare M&A. But healthcare’s more interesting transactions often come from somewhere else: connecting complementary pieces of an increasingly complex system.

The best buyer may not simply be the company most similar to the seller. It may be the company for which the seller makes something new possible.